ES2824763T3 - Tratamiento y a la prevención de la enfermedad de Alzheimer (AD) - Google Patents

Tratamiento y a la prevención de la enfermedad de Alzheimer (AD) Download PDF

Info

Publication number
ES2824763T3
ES2824763T3 ES17189527T ES17189527T ES2824763T3 ES 2824763 T3 ES2824763 T3 ES 2824763T3 ES 17189527 T ES17189527 T ES 17189527T ES 17189527 T ES17189527 T ES 17189527T ES 2824763 T3 ES2824763 T3 ES 2824763T3
Authority
ES
Spain
Prior art keywords
aluminum oxyhydroxide
patient
administered
use according
aluminum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17189527T
Other languages
English (en)
Spanish (es)
Inventor
Markus Mandler
Achim Schneeberger
Bonin Arne Von
Frank Mattner
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2824763T3 publication Critical patent/ES2824763T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17189527T 2014-04-29 2015-04-29 Tratamiento y a la prevención de la enfermedad de Alzheimer (AD) Active ES2824763T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14166354 2014-04-29
EP14166355 2014-04-29

Publications (1)

Publication Number Publication Date
ES2824763T3 true ES2824763T3 (es) 2021-05-13

Family

ID=53039896

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17189527T Active ES2824763T3 (es) 2014-04-29 2015-04-29 Tratamiento y a la prevención de la enfermedad de Alzheimer (AD)
ES15720059.3T Active ES2651537T3 (es) 2014-04-29 2015-04-29 Tratamiento y prevención de la enfermedad de Alzheimer (AD)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15720059.3T Active ES2651537T3 (es) 2014-04-29 2015-04-29 Tratamiento y prevención de la enfermedad de Alzheimer (AD)

Country Status (18)

Country Link
US (1) US10478454B2 (https=)
EP (2) EP3137093B1 (https=)
JP (1) JP6692755B2 (https=)
KR (1) KR102388363B1 (https=)
CN (1) CN106659738B (https=)
AU (1) AU2015254663B2 (https=)
CA (1) CA2946928C (https=)
CY (1) CY1119674T1 (https=)
DK (1) DK3137093T3 (https=)
ES (2) ES2824763T3 (https=)
HR (1) HRP20171896T1 (https=)
HU (1) HUE037501T2 (https=)
LT (1) LT3137093T (https=)
NO (1) NO3137093T3 (https=)
PL (1) PL3137093T3 (https=)
PT (1) PT3137093T (https=)
SI (1) SI3137093T1 (https=)
WO (1) WO2015165966A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (en) * 1993-01-14 1994-07-21 Pollard Harvey B Methods and compositions for blocking amyloid protein ion channels
HUP0004331A3 (en) * 1997-08-21 2001-09-28 Gerolymatos P N Sa Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
BR112012024708A2 (pt) * 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
PL3137094T3 (pl) * 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3137097B1 (en) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)

Also Published As

Publication number Publication date
AU2015254663B2 (en) 2020-04-02
US20170049812A1 (en) 2017-02-23
EP3269376A1 (en) 2018-01-17
EP3137093B1 (en) 2017-09-13
CA2946928C (en) 2023-01-31
CN106659738A (zh) 2017-05-10
EP3137093A1 (en) 2017-03-08
EP3269376B1 (en) 2020-07-15
AU2015254663A1 (en) 2016-11-10
SI3137093T1 (en) 2018-01-31
CY1119674T1 (el) 2018-04-04
CN106659738B (zh) 2021-02-09
CA2946928A1 (en) 2015-11-05
JP6692755B2 (ja) 2020-05-13
HUE037501T2 (hu) 2018-08-28
HRP20171896T1 (hr) 2018-02-23
PL3137093T3 (pl) 2018-06-29
DK3137093T3 (en) 2017-12-11
US10478454B2 (en) 2019-11-19
LT3137093T (lt) 2017-12-11
KR20160145822A (ko) 2016-12-20
ES2651537T3 (es) 2018-01-29
KR102388363B1 (ko) 2022-04-19
NO3137093T3 (https=) 2018-02-10
JP2017518275A (ja) 2017-07-06
WO2015165966A1 (en) 2015-11-05
PT3137093T (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
AU2021200093B2 (en) Treatment and prevention of alzheimer's disease (ad)
ES2824763T3 (es) Tratamiento y a la prevención de la enfermedad de Alzheimer (AD)
WO2015165971A1 (en) Treatment and prevention of alzheimer's disease (ad)